SCHEMBL26057658

SCHEMBL26057658

CC(=O)Nc1cc2c(Nc3cccc(-n4nccn4)c3)ncnc2cc1OCCCN1CCN(C)CC1

nearest known ligand 0.66

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 20/20 0.66
▸ KDR P35968 14/20 0.57
▸ ERBB2 P04626 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26058979 0.93 EGFR (0.67) EGFRKDRERBB2
SCHEMBL30430496 0.91 EGFR (0.80) EGFRKDRERBB2
SCHEMBL25372433 0.91 EGFR (0.80) EGFRKDRERBB2
SCHEMBL25663372 0.90 EGFR (0.59) EGFRKDRERBB2
SCHEMBL25270327 0.84 EGFR (0.55) EGFRKDR
SCHEMBL30549063 0.83 EGFR (0.79) EGFRKDRERBB2
SCHEMBL25211674 0.83 EGFR (0.79) EGFRKDRERBB2
SCHEMBL25221635 0.82 EGFR (0.55) EGFRKDRERBB2
SCHEMBL30549067 0.82 EGFR (0.77) EGFRKDRERBB2
SCHEMBL25247885 0.82 EGFR (0.77) EGFRKDRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271936-A1 EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-08-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271936-A1 EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF EGFR, WEE1, WEE2 EGFR 1/4885KDR 33/4885ERBB2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback